Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
Wegener's Granulomatosis, Vasculitis
About this trial
This is an interventional treatment trial for Wegener's Granulomatosis focused on measuring Induction therapy, ANCA-associated vasculitis, Wegener's granulomatosis, microscopic polyangiitis, mycophenolate mofetil, cyclophosphamide
Eligibility Criteria
Inclusion Criteria: First or second relapse ANCA-associated vasculitis PR3- or MPO-ANCA antibodies present or histological proof of relapse Adult Exclusion Criteria: Severe alveolar bleeding or (imminent) respiratory failure Renal failure (serum creatinine >500 umol/L or dialysis) Maintenance therapy before start of study consisting of: cyclophosphamide > 100 mg/day or prednisolone >25 mg/day Intolerance or allergy for cyclophosphamide, mycophenolate mofetil or azathioprine Gravidity or inadequate anticonception
Sites / Locations
- University Medical Centre GroningenRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
1
2
mycophenolate and steroids as remission induction, followed by azathioprine maintenance therapy
cyclophosphamide